NEW YORK (GenomeWeb) – T2 Biosystems announced after the close of the market today that it has begun a public offering of 3.5 million shares of its common stock.

The company also said it expects to grant the underwriters of the offering a 30-day option to buy an additional 525,000 shares at the public offering price. Goldman Sachs is acting as the book-running manager for the offering. Additional underwriters include Leerink Partners, Canaccord Genuity, and Cantor Fitzgerald.

T2's stock closed at $11.77 in Tuesday trade on the Nasdaq.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

NPR reports that Turkish high school students will no longer study evolution.

Researchers report they sequenced and identified plant species in an "al fresco" laboratory.

An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.

In PNAS this week: host contributors to typhoid fever risk, effects of obesity-related variants near TMEM18, and more.